Probi Competitors

Delisted . USA . 
Stock . Probi AB
Probi AB competes with Hansa Biopharma, Frontage Holdings, Transgene, Cellectis, and Silence Therapeutics; as well as few others. Analyzing Probi AB competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Probi AB to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Probi AB competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details

Probi AB Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Probi AB and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Probi and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Probi AB does not affect the price movement of the other competitor.

High positive correlations

OPORF
+ 1.0
FGHQF
ORYZF
+ 0.8
HNSBF
PRRUF
+ 0.75
TRGNF
PRRUF
+ 0.72
SLNCF
SLNCF
+ 0.71
TRGNF
CYDY
+ 0.53
TRGNF
  

High negative correlations

ORYZF
- 0.75
CYDY
ORYZF
- 0.59
TRGNF
CYDY
- 0.57
HNSBF
TRGNF
- 0.5
HNSBF
CLVLF
- 0.39
CMVLF
ORYZF
- 0.38
SLNCF

Risk-Adjusted Indicators

There is a big difference between Probi Pink Sheet performing well and Probi AB Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Probi AB's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
HNSBF  1.59  0.26  0.00 (0.79) 0.00 
 0.00 
 0.00 
 0.00 
 89.13 
FGHQF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
TRGNF  1.62  0.67  0.00  2.06  0.00 
 0.00 
 0.00 
 0.00 
 61.69 
CMVLF  2.42  1.12  0.00 (1.78) 0.00 
 0.00 
 0.00 
 0.00 
 74.56 
SLNCF  2.61  0.57  0.00  0.81  0.00 
 0.00 
 12.50 
(6.25)
 45.00 
PRRUF  1.96  0.89  0.00  8.22  0.00 
 0.00 
 4.00 
 0.00 
 38.89 
OPORF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CYDY  2.88  0.17  0.01 (0.27) 3.28 
(5.42)
 8.00 
(6.45)
 24.19 
ORYZF  0.21 (0.04) 0.00 (0.03) 0.00 
 0.00 
 0.00 
 0.00 
 13.73 
CLVLF  1.30 (0.04)(0.01)(0.01) 2.55 
(7.15)
 6.40 
(6.33)
 21.68 
All Fundamental Data

Probi AB Competitive Analysis

The better you understand Probi AB competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Probi AB's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Probi AB's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
HNSBF FGHQF TRGNF CMVLF SLNCF PRRUF OPORF CYDY ORYZF CLVLF
 0.00 
 2.91 
Hansa
 0.00 
 0.15 
Frontage
 0.00 
 1.00 
Transgene
 0.00 
 4.50 
Cellectis
 11.11 
 2.00 
Silence
 14.29 
 0.32 
Immutep
 0.00 
 0.24 
Open
 0.00 
 0.28 
Cytodyn
 0.00 
 3.36 
Oryzon
 0.00 
 7.70 
Clinuvel
Market Volatility
(90 Days Market Risk)
Dangerous
Very steady
Abnormally volatile
Very risky
Dangerous
Out of control
Very steady
Out of control
Somewhat reliable
Somewhat reliable
Market Performance
(90 Days Performance)
Weak
Weakest
Fair
Fair
Fair
Good
Weakest
Soft
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Low
Strong
Low
Moderate
Low
Low
Risky
Small
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Buy
Strong Sell
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Current Ratio
6.42
1.81
4.27
3.17
3.76
14.16
1.19
0.08
3.76
10.24
Net Asset
1.01 B
475.84 M
101.84 M
382.08 M
96.19 M
148.52 M
42.27 M
29.18 M
95.38 M
143.95 M
Profit Margin
N/A
0.1
-1.27
N/A
-2.24
N/A
-0.0307
N/A
-0.33
0.32
EBITDA
(538.83 M)
27.64 M
(16.55 M)
(103.2 M)
(45.42 M)
(43.69 M)
3.07 M
(157.59 M)
(6.58 M)
37.35 M
Current Valuation
189.89 M
601.13 M
152.15 M
82.79 M
240.14 M
142.99 M
80.15 M
286.7 M
106.94 M
635.56 M
Price To Book
6.59
2.07
0.0177
0.79
8.36
2.81
2.64
1066.03
1.77
8.27
Operating Margin
N/A
0.14
-1.39
-6.01
-2.99
-7.18
0.0135
N/A
-0.72
0.54
Current Asset
105 M
N/A
51 M
297 M
N/A
22 M
N/A
136.91 K
N/A
20 M
Retained Earnings
N/A
N/A
(500 M)
(206 M)
N/A
(222 M)
N/A
(211.86 M)
N/A
(133 M)
Beta
0.88
0.75
0.79
2.0
0.85
1.95
1.17
0.2
1.02
0.82
Number Of Employees
150
1.5 K
143
294
105
17
218
23
43
11
Shares Outstanding
52.44 M
2.05 B
100.2 M
55.59 M
107.68 M
879.09 M
671.05 M
832.97 M
55.26 M
49.41 M
Cash Flow From Operations
(481.17 M)
44.55 M
(31.94 M)
(104.56 M)
6.81 M
(30.23 M)
(1.56 M)
(77.72 M)
(3.63 M)
39.87 M
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0016
Total Debt
N/A
67.35 M
N/A
18.77 M
52 K
2.11 M
2.26 M
37.35 M
10.35 M
1.26 M
Return On Equity
-0.89
0.0719
-0.36
-0.56
-1.43
-0.38
-0.05
N/A
-0.0685
0.19
Z Score
N/A
5.4
-5.6
4.2
N/A
47.2
25.2
-22.7
7.8
N/A
Return On Asset
-0.27
0.0435
-0.16
-0.24
-0.28
-0.23
0.0066
-1.48
-0.0419
0.18
Book Value Per Share
1.5
0.16
0.55
3.0
0.95
0.11
0.031
-0.14
1.35
2.54
Current Liabilities
19 M
N/A
24 M
58 M
N/A
1000 K
N/A
508.07 K
N/A
2 M
Total Asset
1.01 B
475.84 M
101.84 M
382.08 M
96.19 M
148.52 M
42.27 M
29.18 M
95.38 M
143.95 M
Debt To Equity
2.29
0.21
0.25
0.52
0.022
0.018
0.11
N/A
0.25
0.01
Target Price
N/A
6.62
N/A
N/A
938.67
N/A
N/A
4.0
N/A
N/A
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.04
Shares Owned By Institutions
41.33
15.32
1.7
9.8
27.7
24.04
6.45
0.06
0.72
8.77
Market Capitalization
274.8 M
670.64 M
212.74 M
131.39 M
349.96 M
171.77 M
96.91 M
233.23 M
143.68 M
835.03 M
Price To Earning
-46.57
32.66
-7.42
-13.64
-17.5
-2.5
N/A
-3.14
N/A
34.88
Price To Sales
16.29
3.07
10.71
4.79
21.67
33.12
2.93
1174.39
13.4
10.65
Net Income
(548.28 M)
18.43 M
(19.54 M)
(114.2 M)
(39.41 M)
(32.21 M)
(74 K)
(210.82 M)
(4.69 M)
20.88 M
Earnings Per Share
-0.65
0.01
-0.23
-2.95
-0.53
-0.024
N/A
-0.22
-0.093
0.28
Shares Owned By Insiders
7.37
60.36
N/A
N/A
56.74
4.61
40.93
7.91
18.04
20.55
Revenue
33.88 M
184.44 M
9.99 M
57.29 M
12.41 M
247.66 K
36.86 M
266 K
N/A
65.72 M
Working Capital
86 M
N/A
27 M
239 M
N/A
21 M
N/A
(371.16 K)
N/A
18 M
Cash And Equivalents
60.15 M
72.3 M
49.57 M
153.13 M
51.56 M
80 M
15.93 M
4.68 M
28.72 M
121.51 M
Cash Per Share
1.58
0.04
0.5
3.37
0.57
0.09
0.02
0.01
0.54
2.46
Gross Profit
116.05 M
66.7 M
(15.87 M)
34.18 M
4.96 M
(26.63 M)
4.29 M
(73.28 M)
9.87 M
56.92 M
Day Typical Price
2.91
0.15
1.0
4.5
2.0
0.32
0.24
0.28
3.36
7.7
Accumulation Distribution
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.069
N/A
N/A
Market Facilitation Index
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.02
N/A
N/A
Daily Balance Of Power
0.0
0.0
0.0
0.0
(9,223,372,036,855)
9.2 T
0.0
N/A
0.0
0.0
Period Momentum Indicator
N/A
N/A
N/A
N/A
(0.25)
0.04
N/A
N/A
N/A
N/A
Rate Of Daily Change
1.0
1.0
1.0
1.0
0.89
1.14
1.0
1.0
1.0
1.0
Day Median Price
2.91
0.15
1.0
4.5
2.0
0.32
0.24
0.28
3.36
7.7
Price Action Indicator
N/A
N/A
N/A
N/A
(0.12)
0.02
N/A
N/A
N/A
N/A
Relative Strength Index
N/A
N/A
81.86
68.78
83.8
91.99
N/A
45.86
N/A
50.07
Coefficient Of Variation
3234.65
N/A
951.45
764.31
874.69
584.44
N/A
2961.07
(65,973)
48122.02
Mean Deviation
1.59
N/A
1.62
2.42
2.61
1.96
N/A
2.88
0.2098
1.3
Jensen Alpha
0.258
N/A
0.6747
1.12
0.57
0.8907
N/A
0.1728
(0.04)
(0.04)
Total Risk Alpha
(0.62)
N/A
(0.02)
0.1853
0.0296
0.3293
N/A
(0.33)
(0.14)
(0.38)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.011
N/A
(0.01)
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
30.16
N/A
54.76
Standard Deviation
7.94
N/A
6.76
8.27
5.59
5.31
N/A
4.31
1.2
3.53
Kurtosis
36.59
N/A
63.54
53.13
8.22
41.94
N/A
1.72
32.51
8.95
Potential Upside
N/A
N/A
N/A
N/A
12.5
4.0
N/A
8.0
N/A
6.4
Treynor Ratio
(0.79)
N/A
2.06
(1.78)
0.8051
8.22
N/A
(0.27)
(0.03)
(0.01)
Maximum Drawdown
89.13
N/A
61.69
74.56
45.0
38.89
N/A
24.19
13.73
21.68
Variance
63.07
N/A
45.67
68.45
31.21
28.22
N/A
18.55
1.45
12.45
Market Risk Adjusted Performance
(0.78)
N/A
2.07
(1.77)
0.8151
8.23
N/A
(0.26)
(0.02)
0.0047
Risk Adjusted Performance
0.0308
N/A
0.0827
0.1009
0.089
0.1287
N/A
0.0321
0.0031
0.0095
Skewness
3.0
N/A
7.88
7.02
0.8554
5.93
N/A
0.4716
(0.15)
0.1836
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3.28
N/A
2.55
Information Ratio
0.0202
N/A
0.0925
0.1205
0.0991
0.1551
N/A
0.014
(0.07)
(0.02)
Value At Risk
N/A
N/A
N/A
N/A
(6.25)
N/A
N/A
(6.45)
N/A
(6.33)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(5.42)
N/A
(7.15)
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
5.49
N/A
7.4
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
10.76
N/A
6.49

Probi AB Competition Performance Charts

Five steps to successful analysis of Probi AB Competition

Probi AB's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Probi AB in relation to its competition. Probi AB's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Probi AB in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Probi AB's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Probi AB, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Probi AB position

In addition to having Probi AB in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Conservative Funds Thematic Idea Now

Conservative Funds
Conservative Funds Theme
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Conservative Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Consideration for investing in Probi Pink Sheet

If you are still planning to invest in Probi AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Probi AB's history and understand the potential risks before investing.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Global Correlations
Find global opportunities by holding instruments from different markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY